Additional file 1: of Early alpha-lipoic acid therapy protects from degeneration of the inner retinal layers and vision loss in an experimental autoimmune encephalomyelitis-optic neuritis model

Additional file 1: of Humoral response in experimental autoimmune encephalomyelitis targets neural precursor cells in the central nervous system of naive rodents

Evangelia Kesidou (3402785)
Olga Touloumi (3402788)
Roza Lagoudaki (3402806)
Evangelia Nousiopoulou (3402791)
Paschalis Theotokis (3402794)
Kyriaki-Nepheli Poulatsidou (4608997)
Marina Boziki (519564)
Evangelia Kofidou (4595323)
Nickoleta Delivanoglou (4609000)
Fani Minti (4609003)
Georgios Hadjigeorgiou (377230)
Nikolaos Grigoriadis (261798)
Constantina Simeonidou (3402809)

November 2017

Methods. Experimental groups, EAE induction and evaluation, Cell culture protocol, Preparation of sa...

Additional file 2: of Systemic administration of orexin A ameliorates established experimental autoimmune encephalomyelitis by diminishing neuroinflammation

Laurine Becquet (3446699)
Catalina Abad (60063)
Mathilde Leclercq (6492524)
Camille Miel (6492527)
Laetitia Jean (211208)
Gaëtan Riou (6492530)
Alain Couvineau (2372197)
Olivier Boyer (211211)
Yossan-Var Tan (322523)

March 2019

Figure S1. Effect of orexin A treatment on myeloid profiles in lymph nodes during the course of EAE....

Additional file 3: of Blockade of sustained tumor necrosis factor in a transgenic model of progressive autoimmune encephalomyelitis limits oligodendrocyte apoptosis and promotes oligodendrocyte maturation

Alice Valentin-Torres (5141054)
Carine Savarin (146990)
Joslyn Barnett (5141057)
Cornelia Bergmann (5141060)

April 2018

OPC maturation and recruitment is not impaired in non-lesioned areas during progressive EAE in GFAPγ...

Additional file 3: of Early alpha-lipoic acid therapy protects from degeneration of the inner retinal layers and vision loss in an experimental autoimmune encephalomyelitis-optic neuritis model

Michael Dietrich (2994882)
Niklas Helling (4920577)
Alexander Hilla (4920565)
Annemarie Heskamp (4920580)
Andrea Issberner (4920568)
Thomas Hildebrandt (819634)
Zippora Kohne (4920571)
Patrick Küry (444316)
Carsten Berndt (3427616)
Orhan Aktas (25659)
Dietmar Fischer (217212)
Hans-Peter Hartung (112650)
Philipp Albrecht (171205)

March 2018

Figure S2. The carbonylation of proteins did not change 120 days after EAE immunization. The bar gra...

Additional file 2: of Early alpha-lipoic acid therapy protects from degeneration of the inner retinal layers and vision loss in an experimental autoimmune encephalomyelitis-optic neuritis model

Michael Dietrich (2994882)
Niklas Helling (4920577)
Alexander Hilla (4920565)
Annemarie Heskamp (4920580)
Andrea Issberner (4920568)
Thomas Hildebrandt (819634)
Zippora Kohne (4920571)
Patrick Küry (444316)
Carsten Berndt (3427616)
Orhan Aktas (25659)
Dietmar Fischer (217212)
Hans-Peter Hartung (112650)
Philipp Albrecht (171205)

March 2018

Figure S1. LA treatment days before glutamate induced oxidative stress did not result in improved HT...

Additional file 4: of Early alpha-lipoic acid therapy protects from degeneration of the inner retinal layers and vision loss in an experimental autoimmune encephalomyelitis-optic neuritis model

Michael Dietrich (2994882)
Niklas Helling (4920577)
Alexander Hilla (4920565)
Annemarie Heskamp (4920580)
Andrea Issberner (4920568)
Thomas Hildebrandt (819634)
Zippora Kohne (4920571)
Patrick Küry (444316)
Carsten Berndt (3427616)
Orhan Aktas (25659)
Dietmar Fischer (217212)
Hans-Peter Hartung (112650)
Philipp Albrecht (171205)

March 2018

Figure S3. Optic nerves of sham-EAE, MOG-EAE and MOG-EAE with therapeutic LA treated mice were compa...

Additional file 1: of Celastrol protects mouse retinas from bright light-induced degeneration through inhibition of oxidative stress and inflammation

Minjuan Bian (154295)
Xiaoye Du (578599)
Jingang Cui (578598)
Peiwei Wang (578597)
Wenjian Wang (314196)
Weiliang Zhu (19448)
Teng Zhang (457128)
Yu Chen (1234761)

February 2016

Figure S1. Celastrol protected retinas from light-induced degeneration in BALB/c mice. Figure S2. Ce...

Additional file 5: of Systemic administration of orexin A ameliorates established experimental autoimmune encephalomyelitis by diminishing neuroinflammation

Laurine Becquet (3446699)
Catalina Abad (60063)
Mathilde Leclercq (6492524)
Camille Miel (6492527)
Laetitia Jean (211208)
Gaëtan Riou (6492530)
Alain Couvineau (2372197)
Olivier Boyer (211211)
Yossan-Var Tan (322523)

March 2019

Figure S4. Orexin A does not alter cytokine and chemokine receptor expression in the draining lymph ...

Additional file 1 of Study protocol: fish oil supplement in prevention of oxaliplatin-induced peripheral neuropathy in adjuvant colorectal cancer patients – a randomized controlled trial. (OxaNeuro)

Nina Lykkegaard Gehr (17898280)
Páll Karlsson (17898283)
Signe Timm (5566946)
Signe Christensen (3605513)
Christian Andreas Hvid (17898286)
Jana Peric (17898289)
Torben Frøstrup Hansen (12987262)
Lotte Lauritzen (644882)
Nanna Brix Finnerup (12101776)
Lise Ventzel (16385814)

February 2024

Additional file 1: Supplementary Table 1. Overview of trial outcomes in the OxaNeuro project. Supple...

Additional file 1: of Advancing the pathologic phenotype of giant axonal neuropathy: early involvement of the ocular lens

Diane Armao (6290009)
Thomas Bouldin (6290012)
Rachel Bailey (6290015)
Jody Hooper (4633564)
Diana Bharucha (6290018)
Steven Gray (4113718)

February 2019

Details regarding experimental procedures and immunohistochemistry (IHC). (DOCX 15âkb

Additional file 1: of One-year outcome of combination therapy with intravitreal aflibercept and photodynamic therapy for polypoidal choroidal vasculopathy

Hsin-Yu Weng (6701684)
Tzu-Lun Huang (6701687)
Pei-Yao Chang (6701690)
Jia-Kang Wang (6701693)

May 2019

The raw data of the study. âOne-year outcome of combination therapy with intravitreal aflibercept ...

Additional file 1: of Development of a core outcome set for amblyopia, strabismus and ocular motility disorders: a review to identify outcome measures

Samia Jabri (6318161)
Jamie Kirkham (179425)
Fiona Rowe (3136911)

February 2019

Table S1. PRISMA checklist. This table contains the different sections in the review with the items ...

Additional file 1: of Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimerâs disease: study protocol for a randomised controlled trial (ELAD study)

Grazia Femminella (6553430)
Eleni Frangou (6553433)
Sharon Love (6245381)
Gail Busza (6553436)
Clive Holmes (237359)
Craig Ritchie (3531092)
Robert Lawrence (229647)
Brady McFarlane (6553439)
George Tadros (6553442)
Basil Ridha (6553445)
Carol Bannister (6553448)
Zuzana Walker (573075)
Hilary Archer (6553451)
Elizabeth Coulthard (6553454)
Ben Underwood (6553457)
Aparna Prasanna (6553460)
Paul Koranteng (6553463)
Salman Karim (6553466)
Kehinde Junaid (6553469)
Bernadette McGuinness (237354)
Ramin Nilforooshan (5172128)
Ajay Macharouthu (6553472)
Andrew Donaldson (6553475)
Simon Thacker (6553478)
Gregor Russell (6553481)
Naghma Malik (6553484)
Vandana Mate (6553487)
Lucy Knight (6553490)
Sajeev Kshemendran (6553493)
John Harrison (3512513)
David Brooks (5369636)
Anthony Passmore (6553496)
Clive Ballard (89605)
Paul Edison (6398009)

April 2019

SPIRIT 2013 checklist: items addressed in the clinical trial protocol. (DOC 121 kb

Additional file 1: Table S1. of Recurrent anterior uveitis and subsequent incidence of ankylosing spondylitis: a nationwide cohort study from 2002 to 2013

Baek-Lok Oh (3160947)
Jeong Lee (3447995)
Eun Lee (418436)
Hee Lee (4838031)
Hyeong Yu (4667683)

February 2018

List of steroids and immunosuppressive agents used for defining anterior uveitis. (DOCX 13 kb

Additional file 1: of Treatment with L-citrulline in patients with post-polio syndrome: study protocol for a single-center, randomised, placebo-controlled, double-blind trial

Simone Schmidt (3822559)
Vanya Gocheva (3451784)
Thomas Zumbrunn (118893)
Daniela Rubino-Nacht (3822562)
Ulrike Bonati (847458)
Dirk Fischer (847469)
Patricia Hafner (479961)

March 2017

Recommended items to address in a clinical trial protocol and related documents. (PDF 57 kb

Additional file 1: of Humoral response in experimental autoimmune encephalomyelitis targets neural precursor cells in the central nervous system of naive rodents

Evangelia Kesidou (3402785)
Olga Touloumi (3402788)
Roza Lagoudaki (3402806)
Evangelia Nousiopoulou (3402791)
Paschalis Theotokis (3402794)
Kyriaki-Nepheli Poulatsidou (4608997)
Marina Boziki (519564)
Evangelia Kofidou (4595323)
Nickoleta Delivanoglou (4609000)
Fani Minti (4609003)
Georgios Hadjigeorgiou (377230)
Nikolaos Grigoriadis (261798)
Constantina Simeonidou (3402809)

November 2017

Methods. Experimental groups, EAE induction and evaluation, Cell culture protocol, Preparation of sa...

Additional file 2: of Systemic administration of orexin A ameliorates established experimental autoimmune encephalomyelitis by diminishing neuroinflammation

Laurine Becquet (3446699)
Catalina Abad (60063)
Mathilde Leclercq (6492524)
Camille Miel (6492527)
Laetitia Jean (211208)
Gaëtan Riou (6492530)
Alain Couvineau (2372197)
Olivier Boyer (211211)
Yossan-Var Tan (322523)

March 2019

Figure S1. Effect of orexin A treatment on myeloid profiles in lymph nodes during the course of EAE....

Additional file 3: of Blockade of sustained tumor necrosis factor in a transgenic model of progressive autoimmune encephalomyelitis limits oligodendrocyte apoptosis and promotes oligodendrocyte maturation

Alice Valentin-Torres (5141054)
Carine Savarin (146990)
Joslyn Barnett (5141057)
Cornelia Bergmann (5141060)

April 2018

OPC maturation and recruitment is not impaired in non-lesioned areas during progressive EAE in GFAPγ...

Additional file 3: of Early alpha-lipoic acid therapy protects from degeneration of the inner retinal layers and vision loss in an experimental autoimmune encephalomyelitis-optic neuritis model

Michael Dietrich (2994882)
Niklas Helling (4920577)
Alexander Hilla (4920565)
Annemarie Heskamp (4920580)
Andrea Issberner (4920568)
Thomas Hildebrandt (819634)
Zippora Kohne (4920571)
Patrick Küry (444316)
Carsten Berndt (3427616)
Orhan Aktas (25659)
Dietmar Fischer (217212)
Hans-Peter Hartung (112650)
Philipp Albrecht (171205)

March 2018

Figure S2. The carbonylation of proteins did not change 120 days after EAE immunization. The bar gra...

Additional file 2: of Early alpha-lipoic acid therapy protects from degeneration of the inner retinal layers and vision loss in an experimental autoimmune encephalomyelitis-optic neuritis model

Michael Dietrich (2994882)
Niklas Helling (4920577)
Alexander Hilla (4920565)
Annemarie Heskamp (4920580)
Andrea Issberner (4920568)
Thomas Hildebrandt (819634)
Zippora Kohne (4920571)
Patrick Küry (444316)
Carsten Berndt (3427616)
Orhan Aktas (25659)
Dietmar Fischer (217212)
Hans-Peter Hartung (112650)
Philipp Albrecht (171205)

March 2018

Figure S1. LA treatment days before glutamate induced oxidative stress did not result in improved HT...

Additional file 4: of Early alpha-lipoic acid therapy protects from degeneration of the inner retinal layers and vision loss in an experimental autoimmune encephalomyelitis-optic neuritis model

Michael Dietrich (2994882)
Niklas Helling (4920577)
Alexander Hilla (4920565)
Annemarie Heskamp (4920580)
Andrea Issberner (4920568)
Thomas Hildebrandt (819634)
Zippora Kohne (4920571)
Patrick Küry (444316)
Carsten Berndt (3427616)
Orhan Aktas (25659)
Dietmar Fischer (217212)
Hans-Peter Hartung (112650)
Philipp Albrecht (171205)

March 2018

Figure S3. Optic nerves of sham-EAE, MOG-EAE and MOG-EAE with therapeutic LA treated mice were compa...

Additional file 1: of Celastrol protects mouse retinas from bright light-induced degeneration through inhibition of oxidative stress and inflammation

Minjuan Bian (154295)
Xiaoye Du (578599)
Jingang Cui (578598)
Peiwei Wang (578597)
Wenjian Wang (314196)
Weiliang Zhu (19448)
Teng Zhang (457128)
Yu Chen (1234761)

February 2016

Figure S1. Celastrol protected retinas from light-induced degeneration in BALB/c mice. Figure S2. Ce...

Additional file 5: of Systemic administration of orexin A ameliorates established experimental autoimmune encephalomyelitis by diminishing neuroinflammation

Laurine Becquet (3446699)
Catalina Abad (60063)
Mathilde Leclercq (6492524)
Camille Miel (6492527)
Laetitia Jean (211208)
Gaëtan Riou (6492530)
Alain Couvineau (2372197)
Olivier Boyer (211211)
Yossan-Var Tan (322523)

March 2019

Figure S4. Orexin A does not alter cytokine and chemokine receptor expression in the draining lymph ...

Additional file 1 of Study protocol: fish oil supplement in prevention of oxaliplatin-induced peripheral neuropathy in adjuvant colorectal cancer patients – a randomized controlled trial. (OxaNeuro)

Nina Lykkegaard Gehr (17898280)
Páll Karlsson (17898283)
Signe Timm (5566946)
Signe Christensen (3605513)
Christian Andreas Hvid (17898286)
Jana Peric (17898289)
Torben Frøstrup Hansen (12987262)
Lotte Lauritzen (644882)
Nanna Brix Finnerup (12101776)
Lise Ventzel (16385814)

February 2024

Additional file 1: Supplementary Table 1. Overview of trial outcomes in the OxaNeuro project. Supple...

Additional file 1: of Advancing the pathologic phenotype of giant axonal neuropathy: early involvement of the ocular lens

Diane Armao (6290009)
Thomas Bouldin (6290012)
Rachel Bailey (6290015)
Jody Hooper (4633564)
Diana Bharucha (6290018)
Steven Gray (4113718)

February 2019

Details regarding experimental procedures and immunohistochemistry (IHC). (DOCX 15âkb

Additional file 1: of One-year outcome of combination therapy with intravitreal aflibercept and photodynamic therapy for polypoidal choroidal vasculopathy

Hsin-Yu Weng (6701684)
Tzu-Lun Huang (6701687)
Pei-Yao Chang (6701690)
Jia-Kang Wang (6701693)

May 2019

The raw data of the study. âOne-year outcome of combination therapy with intravitreal aflibercept ...

Additional file 1: of Development of a core outcome set for amblyopia, strabismus and ocular motility disorders: a review to identify outcome measures

Samia Jabri (6318161)
Jamie Kirkham (179425)
Fiona Rowe (3136911)

February 2019

Table S1. PRISMA checklist. This table contains the different sections in the review with the items ...

Additional file 1: of Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimerâs disease: study protocol for a randomised controlled trial (ELAD study)

Grazia Femminella (6553430)
Eleni Frangou (6553433)
Sharon Love (6245381)
Gail Busza (6553436)
Clive Holmes (237359)
Craig Ritchie (3531092)
Robert Lawrence (229647)
Brady McFarlane (6553439)
George Tadros (6553442)
Basil Ridha (6553445)
Carol Bannister (6553448)
Zuzana Walker (573075)
Hilary Archer (6553451)
Elizabeth Coulthard (6553454)
Ben Underwood (6553457)
Aparna Prasanna (6553460)
Paul Koranteng (6553463)
Salman Karim (6553466)
Kehinde Junaid (6553469)
Bernadette McGuinness (237354)
Ramin Nilforooshan (5172128)
Ajay Macharouthu (6553472)
Andrew Donaldson (6553475)
Simon Thacker (6553478)
Gregor Russell (6553481)
Naghma Malik (6553484)
Vandana Mate (6553487)
Lucy Knight (6553490)
Sajeev Kshemendran (6553493)
John Harrison (3512513)
David Brooks (5369636)
Anthony Passmore (6553496)
Clive Ballard (89605)
Paul Edison (6398009)

April 2019

SPIRIT 2013 checklist: items addressed in the clinical trial protocol. (DOC 121 kb

Additional file 1: Table S1. of Recurrent anterior uveitis and subsequent incidence of ankylosing spondylitis: a nationwide cohort study from 2002 to 2013

Baek-Lok Oh (3160947)
Jeong Lee (3447995)
Eun Lee (418436)
Hee Lee (4838031)
Hyeong Yu (4667683)

February 2018

List of steroids and immunosuppressive agents used for defining anterior uveitis. (DOCX 13 kb

Additional file 1: of Treatment with L-citrulline in patients with post-polio syndrome: study protocol for a single-center, randomised, placebo-controlled, double-blind trial

Simone Schmidt (3822559)
Vanya Gocheva (3451784)
Thomas Zumbrunn (118893)
Daniela Rubino-Nacht (3822562)
Ulrike Bonati (847458)
Dirk Fischer (847469)
Patricia Hafner (479961)

March 2017

Recommended items to address in a clinical trial protocol and related documents. (PDF 57 kb

Additional file 1: of Humoral response in experimental autoimmune encephalomyelitis targets neural precursor cells in the central nervous system of naive rodents

Evangelia Kesidou (3402785)
Olga Touloumi (3402788)
Roza Lagoudaki (3402806)
Evangelia Nousiopoulou (3402791)
Paschalis Theotokis (3402794)
Kyriaki-Nepheli Poulatsidou (4608997)
Marina Boziki (519564)
Evangelia Kofidou (4595323)
Nickoleta Delivanoglou (4609000)
Fani Minti (4609003)
Georgios Hadjigeorgiou (377230)
Nikolaos Grigoriadis (261798)
Constantina Simeonidou (3402809)

November 2017

Methods. Experimental groups, EAE induction and evaluation, Cell culture protocol, Preparation of sa...

Additional file 2: of Systemic administration of orexin A ameliorates established experimental autoimmune encephalomyelitis by diminishing neuroinflammation

Laurine Becquet (3446699)
Catalina Abad (60063)
Mathilde Leclercq (6492524)
Camille Miel (6492527)
Laetitia Jean (211208)
Gaëtan Riou (6492530)
Alain Couvineau (2372197)
Olivier Boyer (211211)
Yossan-Var Tan (322523)

March 2019

Figure S1. Effect of orexin A treatment on myeloid profiles in lymph nodes during the course of EAE....

Additional file 3: of Blockade of sustained tumor necrosis factor in a transgenic model of progressive autoimmune encephalomyelitis limits oligodendrocyte apoptosis and promotes oligodendrocyte maturation

Alice Valentin-Torres (5141054)
Carine Savarin (146990)
Joslyn Barnett (5141057)
Cornelia Bergmann (5141060)

April 2018

OPC maturation and recruitment is not impaired in non-lesioned areas during progressive EAE in GFAPγ...

Additional file 1: of Early alpha-lipoic acid therapy protects from degeneration of the inner retinal layers and vision loss in an experimental autoimmune encephalomyelitis-optic neuritis model

Abstract

Extracted data

Additional file 1: of Early alpha-lipoic acid therapy protects from degeneration of the inner retinal layers and vision loss in an experimental autoimmune encephalomyelitis-optic neuritis model

Abstract

Extracted data

Related items

Related items